|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | |
| A61P 35/02 | |||
| C07K 16/28 |
| (11) | Patento numeris | 2701741 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12724289.9 |
| Europos patento paraiškos padavimo data | 2012-04-30 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-03-05 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-06-10 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2012/001857 |
| Data | 2012-04-30 |
| (87) | Numeris | WO 2012/146394 |
| Data | 2012-11-01 |
| (30) | Numeris | Data | Šalis |
| 201161479961 P | 2011-04-28 | US |
| (72) |
NAGORSEN, Dirk, DE
|
| (73) |
Amgen Research (Munich) GmbH,
Staffelseestrasse 2, 81477 München,
DE
|
| (54) | DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS |
| DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS |